Accéder au contenu
Merck
Toutes les photos(1)

Documents

H1200000

Hydrochlorothiazide

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide, 6-Chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C7H8ClN3O4S2
Numéro CAS:
58-93-5
Poids moléculaire :
297.74
Numéro MDL:
MFCD00051765
Code UNSPSC :
41116107
ID de substance PubChem :
329815156
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

hydrochlorothiazide

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl

InChI

1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)

Clé InChI

JZUFKLXOESDKRF-UHFFFAOYSA-N

Informations sur le gène

human ... SLC12A3(6559)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Hydrochlorothiazide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Carbonic anhydrase inhibitor

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Warning

Mentions de danger

H351

Classification des risques

Carc. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 6

1 of 6

Bisoprolol fumarate European Pharmacopoeia (EP) Reference Standard

Y0000812

Bisoprolol fumarate

4-Amino-6-chloro-1,3-benzenedisulfonamide 98%

Sigma-Aldrich

308560

4-Amino-6-chloro-1,3-benzenedisulfonamide

Chlorothiazide Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1179

Chlorothiazide

Amlodipine besylate United States Pharmacopeia (USP) Reference Standard

USP

1029501

Amlodipine besylate

Valsartan Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1315

Valsartan

Diclofenac sodium salt analytical standard

Supelco

93484

Diclofenac sodium salt

Soham Rej et al.
Drugs & aging, 31(12), 911-916 (2014-10-22)
Little is known about how lithium should be dosed to achieve therapeutic but safe serum concentrations in older adults. In this paper, we investigate how the lithium dose-concentration ratio changes across the lifespan. This was a cross-sectional analysis of 63
Dragos Vinereanu et al.
American heart journal, 168(4), 446-456 (2014-09-30)
The objective of this study is to compare the effects of 2 types of diuretics, indapamide and hydrochlorothiazide, added to an angiotensin-converting enzyme inhibitor, on ventricular and arterial functions in patients with hypertension and diabetes. This is a prospective, randomized
James J DiNicolantonio
Expert opinion on pharmacotherapy, 13(6), 807-814 (2012-03-20)
Hydrochlorothiazide (HCTZ) has not been shown to reduce mortality or cardiovascular events when given as a single agent. In fact, HCTZ increased cardiovascular death and coronary artery disease (CAD) compared to placebo and usual care in 2 randomized trials, yet
Sverre E Kjeldsen et al.
Journal of clinical hypertension (Greenwich, Conn.), 15(6), 380-388 (2013-06-05)
Older patients frequently receive angiotensin II receptor blocker/diuretic combinations to control blood pressure (BP), although there have been relatively few trials specifically examining this patient population. A pooled analysis was performed of data from 7 randomized trials of telmisartan/hydrochlorothiazide combinations
Franz H Messerli et al.
The American journal of medicine, 124(10), 896-899 (2011-10-04)
Hydrochlorothiazide (HCTZ) has become by far the most commonly prescribed antihypertensive drug in the US. In 2008, 47.8 million prescriptions were written for HCTZ alone and 87.1 million prescriptions for HCTZ combinations. However, there is no evidence that HCTZ in
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique